530 results about "Intravenous therapy" patented technology

The present disclosure provides methods of treating opioid use disorder in a patient in need thereof by intravenously administering to the patient a therapeutically effective amount of ibogaine or pharmaceutically acceptable salt thereof.

Methods of administering sotalol hydrochloride in an amount effective for treating one or more cardiovascular disease or disorder in pediatric patients are described and include IV and / or oral doses based on age-specific creatinine clearance ranges.

The invention discloses a pharmaceutical composition for reversing pancreatic cancer gemcitabine drug resistance and application of the pharmaceutical composition, and belongs to the technical field of biological medicine. The composition comprises a generic FGFR inhibitor delatinib and gemcitabine, the concentration of the delatinib is 25 to 50 mg / kg, and the concentration of the gemcitabine is 20 to 30 mg / kg. By inhibiting an FGFR2 / FGFR3 signal channel and reducing the expression of FGFR protein in drug-resistant cells, the chemosensitivity of gemcitabine is synergistically enhanced, the apoptosis induction rate is increased by more than two times, and the synergic index (CI) is less than 1. In-vitro and nude mouse transplantation tumor experiments prove that the composition can significantly inhibit the proliferation of gemcitabine drug-resistant pancreatic cancer cells. The Gemcitabine drug-resistant pancreatic cancer drug can be used for preparing a drug for treating Gemcitabine drug-resistant pancreatic cancer with high FGFR3 expression, patients are screened through immunohistochemistry or gene sequencing, intravenous injection or oral administration is adopted, dosage forms comprise freeze-dried powder injection, capsules or tablets, and a new strategy is provided for pancreatic cancer drug-resistant treatment.

The disclosure relates to methods, compositions, and combinations for detoxification in a patient comprising performing therapeutic plasma exchange (TPE) on the patient. The disclosure also relates to methods, compositions, and combinations for removing toxins in a patient as a result of chronic exposure to the toxins, comprising performing one or more TPE sessions on the patient and administering an oral composition to the patient. The methods, compositions, and combinations of the disclosure may also be used to replenish biomarkers indicative of a healthy state of the body in order to improve immune system function or patient longevity, and / or reduce oxidative stress or inflammation. The methods, compositions, and combinations of the disclosure may also be used to reduce the level of atherosclerosis, improve cognitive function, prevent early cancer development, promote immune health, and / or treat health conditions or diseases such as autoimmune diseases, cancers, Alzheimer's disease, Parkinson's disease, chronic fatigue syndromes, or fibromyalgia. Additionally, the methods, compositions, and combinations of the disclosure may comprise an intravenous supplementation, wherein each TPE session is followed by administration to the patient of an IV composition. The disclosure further relates to oral compositions and IV compositions for use in the methods, compositions, and combinations of the disclosure.

The invention provides a fusion platform intelligent teaching method and system based on virtual simulation, and the method comprises the steps: obtaining an operation behavior of a student at each interaction point in a virtual simulation scene, and forming an IFM data set; constructing an evaluation function, and comparing the actual performance data with the ideal performance value; forming a key evidence source data set based on actual performance data in the IFM data set; and constructing an optimization model containing data conflict items and consistency items of each key evidence source, generating teaching guidance data, and quantitatively evaluating the learning effect of students. According to the invention, students can perform operation exercises in a simulated real clinical scene, such as key nursing skills of intravenous injection, external chest compression and the like, and through multi-dimensional data collection including operation accuracy, answer conditions, interactive records and the like, more comprehensive learning evaluation is provided, so that scoring deviation caused by single data is avoided, and the learning efficiency is improved. And a rich information basis is provided for ability evaluation of students.

The invention discloses an RGD-click chemical crosslinking siRNA nano-carrier, a preparation method thereof and application of the nano-carrier in preparation of a medicine for treating secondary thyroidism, and belongs to the technical field of medicines.The nano-carrier is RGD-PEG-PLys (N), and the preparation method of the nano-carrier comprises the steps of synthesis of PLys (ss-DBCO), synthesis of RGD-PEG-PLys (N) and the like. According to the application, the nano-carrier is used for preparing siRNA composite nanoparticles; vascular endothelial targeting (RGD), dynamic stability (click crosslinking) and microenvironment responsiveness (disulfide bond) are organically combined for the first time to achieve mutual synergistic interaction, and the effect ceiling of an existing material is broken through; according to the siRNA composite nanoparticle, the silence effect of the PTH gene as long as 70 days can be achieved through single intravenous injection, the PTH inhibition rate is larger than 85%, the siRNA accumulation amount in parathyroid gland tissue is remarkably increased through RGD targeting (8.6 times that of a non-targeting group), the liver and kidney distribution amount is reduced by 60%, and the system toxicity is controllable.

A drug delivery system includes a packaging housing a first component including at least one of a drug product, a diluent, a saline solution, or an IV stabilizing solution (“IVSS”) and a second component comprising at least one of the drug product, the diluent, the saline solution, and the IVSS, the first component being different than the second component. The first component is disposed in a first container in a storage state and the first container is positioned in a first compartment of the packaging housing. The second component is disposed in a second container in a storage state and the second container is positioned in a second compartment of the packaging housing. At least one of the first compartment and the second compartment may include an individual seal and wherein each of the individual seals and the first and second compartments are sterilized.

A liquid transfer device is provided having a trifurcated body that includes a vial adapter at a first end configured to telescopically mount on the crown of an IV bottle to puncture a stopper in the crown with a cannula, an IV port extending from an opposing second end of the trifurcated body, and a needleless self-sealing port extending from a third end of the trifurcated body and configured to couple with the male connector of an additive transfer device. Methods of using the liquid transfer device with an IV bottle, additive transfer device, and an infusion set to prepare an infusion liquid for administration to a patient are also provided.

The invention belongs to the technical field of drug delivery, and particularly relates to an M-coated PLGA-10BX compound as well as a preparation method and application thereof. The preparation method comprises the following steps: preparing 10B-enriched boron nitride (h-10BN); extracting a cell membrane of the macrophage RAW264.7; polylactic acid-glycolic acid copolymer (PLGA) nano particles loaded with h-10BN are prepared; and finally, the bionic nano platform M (at) PLGA-10BN based on the macrophage membrane is prepared. The bionic nano-platform prepared by the invention is uniform in particle size and morphology, has relatively high biological safety, and has no obvious damage to various tissues and visceral organs. The compound can be used as a general platform for boron compound delivery, can also be used as an immune activator, is suitable for intravenous injection administration, and expands the application of boron neutron capture therapy (BNCT) in treatment of glioblastoma (GBM).

The invention relates to a noninvasive solid tumor internal hypoxia condition detection method, which comprises: chemically modifying a near-infrared two-region fluorophore, an oxygen sensitive group and a tumor targeting group to construct a composite probe, collecting fluorescence and photoacoustic signals of a tumor region after intravenous injection, carrying out de-noising analysis, and combining with multiple parameters to solve hypoxia concentration change, a four-dimensional space-time distribution map is constructed by fusing vascular topological data, and individualized calibration is realized through microfluidic simulation and Bayesian optimization. Compared with a traditional invasive detection and single-mode imaging technology, the advantages of bimodal signals are integrated in a breakthrough mode, non-invasive, real-time and high-resolution dynamic hypoxia monitoring is achieved, acute and chronic hypoxia areas are accurately distinguished, tumor blood vessel heterogeneity interference is reduced through personalized parameter calibration, and the accuracy of hypoxia monitoring is improved. High-precision spatio-temporal data support based on hypoxia microenvironment monitoring is provided for solid tumor radiotherapy target planning, chemotherapy drug delivery optimization, chemotherapy drug resistance and curative effect prediction and evaluation and tumor metastasis progress risk analysis.

The invention relates to the technical field of biomedicine, in particular to a mouse intrahepatic bile duct cancer cell strain and a construction method and application thereof, the cell strain is named as mouse intrahepatic bile duct cancer cell strain KP-ICC and preserved in China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: C202574; the cell strain is derived from a KrasG12D / Tp53flox / flox C57BL / 6J mouse, a spontaneous tumor model is constructed through high-pressure hydrodynamic tail vein injection of pT3-Cre and a sleep beauty transposase plasmid, and the spontaneous tumor model is obtained through in-vitro culture, passage, monoclonal screening and tumorigenicity verification. The KP-ICC cell strain naturally has chemotherapy-immune combined treatment drug resistance and ferroptosis resistance characteristics, and can be widely applied to the fields of intrahepatic cholangiocarcinoma drug resistance mechanism research, drug resistance reversing, combined treatment drug development, drug resistance animal model establishment and the like.

The invention discloses a method for constructing an atrial fibrillation small animal model through succinic acid induction and application, and the method comprises the following steps: in an animal model construction period, enabling a small animal to ingest an aqueous solution containing succinic acid or all pharmaceutically acceptable salts of succinic acid every day, and finishing the modeling period to obtain the animal model. Compared with a traditional angiotensin AngII administration method, the atrial fibrillation small animal model has the advantages that the cost of a medicine for constructing the animal model is lower, the economic benefit is higher, and the atrial fibrillation induction effect is better; the model represents the most common atrial fibrillation type in clinic, and compared with an acute transient atrial fibrillation model, the research and application range is wider; compared with tail vein injection, intraperitoneal injection, subcutaneous pump burying and other modes, the non-creative model has the advantages that damage to small animals is smaller, and the requirement for the operation technology is low.

The present invention relates to a novel long-acting injectable composition comprising finasteride for the prevention or treatment of androgenetic alopecia. The composition inhibits type II 5α-reductase with a single injection lasting over one month, thereby suppressing the conversion of testosterone to DHT and reducing androgen-mediated follicular miniaturization. In addition, after injection into the body, the average elimination half-life (T1 / 2el) of finasteride can be increased to enhance stability and provide more predictable and uniform therapeutic effects compared to oral formulations.

The invention provides a device for injecting caudal veins of mice, which relates to the field of biomedical engineering, and comprises a fixed table body, a mouse body fixing cylinder, a placing groove, a mouse tail fixing table, an overturning support frame, an overturning driving motor, a clamping chuck, a fixed adjusting mechanism and a tail overturning driving mechanism, the mouse body fixing cylinder is fixedly connected to the upper portion of the fixing table body. The placing groove is formed in the upper part of the mouse body fixing cylinder; the rat tail fixing table is fixedly connected to the rear side of the upper portion of the fixing table body. The overturning driving motor is fixedly connected to the upper end of the rear portion of the overturning supporting frame. The clamping chuck is rotationally connected to the front portion of the overturning supporting frame. The fixed adjusting mechanism is arranged on the upper portion of the interior of the fixed table body. The tail turning driving mechanism is arranged behind the mouse tail fixing table, intravenous injection operation of experimenters is facilitated, the mouse tail intravenous injection operation efficiency is improved, and the problems that the experimenters need to twist the mouse tail with one hand and operate an injector with the other hand during injection, and operation is inconvenient are solved.

The invention relates to the technical field of hyaluronic acid derivatives and nano drug delivery systems, in particular to a lipoic acid grafted hyaluronic acid derivative, a preparation method and application, and provides a lipoic acid grafted hyaluronic acid derivative with a structure that lipoic acid is grafted with hyaluronic acid through a thioketal bond. A lipoic acid grafted hyaluronic acid derivative loaded IAA drug delivery system is constructed, can be gathered at a colitis disease part through intravenous injection, and is actively absorbed by cells by virtue of the affinity effect of hyaluronic acid in a lipoic acid grafted hyaluronic acid derivative structure on CD44 receptors on the surfaces of inflammatory cells; according to the present invention, with the application of the IAA in the cell, the responsive structure degradation occurs in the intracellular high oxidative stress environment, and the IAA is delivered into the cell in the positioning manner, such that the IAA inhibits the inflammation generation by activating the AhR and the downstream oxidative stress and inflammatory reaction related pathway so as to promote the mucous membrane repair, and the problem that the colitis treatment drug cannot accurately act on the focus in the prior art is solved.

The invention relates to the technical field of medicines, in particular to application of lycium barbarum-derived extracellular vesicles in preparation of a medicine for treating acute kidney injury. The used extracellular vesicles derived from Chinese wolfberry fruits have a lipid bilayer membrane structure, are good in stability, free of remarkable toxicity, good in blood compatibility and high in-vivo safety after long-term intravenous injection, are used for preparing the medicine for treating the acute kidney injury, and can reduce apoptosis, inhibit rising of blood urea nitrogen and creatinine levels and relieve injury of kidney tissues; the invention further provides application of the extracellular vesicles derived from the Chinese wolfberry fruits in preparation of the medicine for treating the lung injury disease, the weight loss is relieved, lung tissue is protected, meanwhile, the pulmonary alveolar-capillary barrier can be repaired, and in addition, the medicine can be used for treating the lung injury disease. The invention also provides application of the extracellular vesicles derived from Chinese wolfberry fruits in preparation of nuclear transcription factor kappa B inhibitors and / or inhibition of apoptosis and / or repair of pulmonary alveolar capillary barriers.

The invention provides a POCD treatment medicine composition with dendrobine delivered by a nano-carrier and application, and belongs to the technical field of medicine. The composition consists of dendrobine, a nano-carrier material and a stabilizer, wherein a nano-carrier is PLGA (poly (lactic-co-glycolic acid)) nanoparticles or lipidosome. The particle size of the composition is 50-150nm, the polydispersity index is less than 0.3, and the loading capacity of dendrobine is 5-15%. The invention also provides two preparation methods of the composition. The PLGA nanoparticles are prepared by adopting an emulsification-solvent evaporation method; the liposome is prepared by adopting a film hydration-ultrasonic extrusion method, and each process parameter is specifically limited. The pharmaceutical composition can significantly improve the brain targeting and bioavailability of dendrobine, and can be used for preparing drugs for preventing or treating postoperative cognitive impairment (POCD), and the administration route can be intravenous injection or nasal administration.

The invention discloses a lipidosome drug delivery system for targeted therapy of brain glioma and application thereof. The lipidosome drug delivery system is a lipidosome mixture prepared from a basic component, a functional component and an external water-phase buffer solution. After intravenous injection, the liposome is efficiently combined with complement protein C3 and immune globulin M in plasma to synergistically activate a complement system, actively attracts and activates neutrophils to uptake, and crosses a blood brain barrier in a mode of'building a defecation vehicle 'by utilizing the inflammatory taxis of the neutrophils. Neutrophile granulocytes are stimulated by inflammatory factors in a microenvironment after reaching a tumor brain area to form extracellular trap release lipidosome. The lipidosome realizes specific targeting through folate receptors over-expressed on the surfaces of glioma cells. The liposome shows excellent cross-blood-brain-barrier drug delivery efficiency and brain glioma curative effect in vivo, can be effectively combined with surgery, radiotherapy and the like, and provides a solution for the main problems of radiotherapy resistance, chemotherapy drug resistance and the like in clinic.

The invention provides a nano-drug based on cfDNA, ROS and Ca < 2 + > removal and NO release promotion strategies and a preparation method and application thereof, the preparation method comprises the following steps: weighing polyethyleneimine PEI and L-arginine in deionized water to prepare a template PEI-arg; adding a calcium ion chelating agent into the template, uniformly mixing, freezing and standing; a polyethyleneimine arginine template simulates biomineralization reaction catalysis and is doped with a calcium ion chelating agent to prepare the nano-drug PEI-arg (at) MON (at) BA. The bionic silicon dioxide nano-drug is successfully prepared by adopting a one-step method, and the nano-system removes free DNA through electrostatic adsorption, eliminates ROS through redox reaction, chelates excessive Ca < 2 + > by virtue of complexation, and continuously releases NO through arginine biotransformation. Benefited from the passive targeting characteristic of the liver, the nano scavenger is enriched to the liver after intravenous injection, so that the liver microcirculation can be remarkably improved, the oxidative stress level can be reduced, the inflammatory cascade reaction can be reduced, and the tissue pathological injury can be effectively relieved.

A system and method for determining a patient's fluid-dependent hemodynamic responsiveness. The system comprises a processor configured to receive one or more of: one or more patient characteristics, one or more surgery characteristics, or one or more measured patient blood parameters. The processor is further configured to receive fluid challenge characteristics for a fluid challenge administered intravenously to the patient, and one or more measurements indicative of the patient heart function before and after the administration of the fluid challenge. The processor determines the patient blood volume (BV) within the patient's central blood compartment, before and after the administration of the fluid challenge, based on the received fluid challenge characteristics and the received one or more of: one or more patient characteristics, one or more surgery characteristics, or one or more measured patient blood parameters. The processor then calculates the relationship between the change in patient blood volume (ABV) and the change in patient heart function.

The invention relates to the technical field of exosome preparations, and particularly discloses an exosome nasal delivery preparation as well as a preparation method and application thereof. The preparation comprises the following components: 1 * 10 < 9 >-5 * 10 < 11 > particle number / ml of exosome, 1%-4% w / v of a saccharide protective agent, 0.5%-4.5% w / v of an alcohol protective agent, 0.05%-1% w / v of an absorption enhancer and a solvent. The exosome nasal delivery preparation can break through the blood brain barrier and quickly take effect, and the intracerebral delivery efficiency of the exosome nasal delivery preparation can be improved by 2-5 times compared with intravenous injection. The nasal administration preparation can be used for treating central nervous system diseases such as cerebral apoplexy and the like, and can remarkably improve the neurological function, reduce the cerebral infarction area and promote functional recovery.

An anesthetic equipment storage and waste air management module configured to housing electronic and electromechanical surgical equipment including a system to measure and record administration of one or more IV medications or fluids for IV administration. The module can include a housing having a lower section and a tower-like upper section, wherein the lower section is configured to house unrelated waste heat-producing electronic and electromechanical surgical equipment. The module can also include a cowling that substantially confines waste heat generated by the unrelated waste heat-producing electronic and electromechanical surgical equipment, and can include a system for measuring and recording the administration of the one or more IV medications and fluids.

The application provides a multifunctional nano particle for targeting abdominal aortic aneurysm and a preparation method and application thereof, and belongs to the field of nanobiomedicine, wherein polyphenol oxidation self-polymer nanoparticles are used as carriers, doxycycline is loaded, and a targeting ligand cRGD is modified on the surface of the nano carrier; the neovasculature in the media and adventitia of AAA sites helps accumulation of the nanoparticles in the abdominal aortic aneurysm, and the integrin αν3 beta receptor highly expressed on the surface of the diseased cell membrane can recognize the cRGD with high affinity, and then mediate the targeted endocytosis of the nanoparticles; after intravenous injection, the nanoparticles can be effectively enriched in the lesion site and achieve long-term retention, and can release DC in response to the high ROS level in the tumor microenvironment; the drug is rapidly released to take effect, and the non-specific toxic side effects are reduced; the free radical scavenging capacity of the nanoparticles can be synergized with the DC activity to treat AAA through multiple mechanisms such as anti-inflammatory, antioxidant, macrophage repolarization promotion, anti-apoptosis and calcification inhibition, and MMPs inhibition.

The invention discloses an intravenous injection medicine preparation device. The intravenous injection medicine preparation device comprises an outer cylinder and an inner pushing assembly. The outer cylinder comprises a cylinder body and an inner guide piece; wherein the inner guide piece is arranged in the cylinder body, and the inner guide piece and the cylinder body are arranged in a concentric circle shape; the inner pushing assembly comprises a pulling piece and a stirring part; the bottom end of the pulling piece is inserted into the barrel, and the top of the pulling piece is arranged outside the barrel. The stirring part is composed of a stirring piece, a transmission piece and a pushing piece; wherein the pushing piece is arranged in the pulling piece and synchronously moves along with the pulling piece in a single direction; through the design, the stirring part is additionally arranged in the internal structure of a conventional configuration device, after various liquid medicines are sucked through the configuration device, the stirring part can directly and fully stir the sucked liquid medicines, and the situation that the various liquid medicines are injected into the same container one by one and then mixed through manual shaking is not needed; through the improvement, the liquid medicine mixing process is more convenient and efficient.

The present invention provides methods of treating or preventing atrial fibrillation, atrial flutter, or a combination thereof comprising intravenously administering sotalol hydrochloride to a subject in need thereof. Embodiments of the present invention further provide novel methods of intravenously administering sotalol hydrochloride for example in pediatric patients. The present invention provides a novel intravenous, prophylactic, antiarrhythmic method of sotalol administration.

The invention relates to medicine, in particular to gerontology and therapy and can be used for treating sarcopenia in elderly patients.Summary of the invention consists in alternating for 1…2 days the intravenous administration of ozonized 0.9% NaCl solution and major autohemotherapy, namely 500 mL of a 0.9% NaCl solution ozonized with an ozone-oxygen mixture, with an ozone concentration of 5…10 µg / mL, are administered, and major autohemotherapy consists in collecting 300…400 mL of venous blood from the patient, which is ozonized, with an ozone concentration of 15 µg / mL and transfused to the patient, the treatment course includes 8…10 consecutive procedures, then it is extended with minor autohemotherapy, which consists in collecting 5…10 mL of venous blood, which is ozonized, with an ozone concentration of 15 µg / mL and administered intramuscularly every 10th day of alternation and includes 3 consecutive procedures, and the ozonized 0.9% NaCl solution is administered for up to 6…8 weeks.

The present invention discloses a liquid-gas jointly controlled sequential automatic bottle-changing infusion set, which includes a first flow channel, a rear flow channel, and a liquid-gas joint controller arranged between the first flow channel and the rear flow channel. The first flow channel is connected to a first medicine bottle and an intravenous injection needle. The upper end of the rear flow channel is connected to a medicine bottle at the rear, and the lower end is connected to the first flow channel below the liquid-gas joint controller after passing through the liquid-gas joint controller. The liquid-gas joint controller is provided with an air inlet channel, and the air inlet channel bifurcates in the liquid-gas joint controller to form a prior airway and a rear airway leading to the outside of the liquid-gas joint controller. The prior airway is connected to a prior medicine bottle, and the rear airway is connected to a medicine bottle at the rear. When the liquid-gas joint controller opens the rear flow channel, the prior airway is synchronously closed, and all prior medicine bottles stop admitting air, so that the remaining liquid medicine in all prior medicine bottles is forced to stop flowing downward. Its advantages are as follows: it can realize simultaneous hanging of multiple medicine bottles and sequential automatic bottle-changing drip infusion; it can avoid excessive mixing of the liquid medicine in the rear medicine bottle with the residual liquid medicine in the prior medicine bottle during the drip infusion.

The invention relates to a non-gadolinium magnetic resonance contrast agent and a preparation method thereof, and belongs to the field of contrast agents. The invention aims to provide a non-gadolinium contrast agent with high biological safety aiming at the risks of renal fibrosis and cerebral deposition existing in a gadolinium-based magnetic resonance contrast agent. The invention provides a phosphate group modified non-gadolinium magnetic resonance contrast agent. The phosphate group modified non-gadolinium magnetic resonance contrast agent consists of a ligand of a phosphate group substituted trans-cyclohexanediamine tetraacetic acid derivative (tmPCDTA or tqPCDTA) and metal ions Fe < 3 + > or Mn < 2 + >, the contrast agent disclosed by the invention is high in biological safety: endogenous Fe < 3 + > / Mn < 2 + > is used for replacing gadolinium, and cell experiments prove that the survival rate of 4T1 cells is not influenced at the concentration of 500 mu M; clinical applicability is high, kidney excretion is rapid, bladder signals are enhanced 3-5 minutes after mouse intravenous injection, and liver retention is avoided.

The application discloses a kind of hardness correlation liver cancer lung premetastatic niche mouse model construction method, it includes the following steps: (1) in vitro enrichment respectively on the low hardness substrate of hardness 6kPa and the high hardness substrate of hardness 16kPa, the condition culture supernatant of mouse liver cancer cell Hepa1-6 that is cultured and grows, respectively named mL-CM and mH-CM;(2) mL-CM and mH-CM are respectively injected into two groups of mice using tail vein injection mode, every 1 day injection 1 time, until the 26th day, during continuous monitoring the recruitment of BMDCs in fresh lung tissue, while with the induction endpoint, i.e. 26th day premetastatic niche mark feature detection includes lung tissue matrix remodeling, immunosuppression, angiogenesis, vascular permeability and inflammation etc..The method has the advantages of short modeling cycle, easy operation, controllable induction condition, can comprehensively and accurately evaluate the common characteristics of liver cancer lung premetastatic niche formation etc..

The invention relates to an ultrasonic response bionic piezoelectric nano-drug for treating epilepsy as well as a preparation method and application of the ultrasonic response bionic piezoelectric nano-drug. The ultrasonic response bionic piezoelectric nano-drug comprises hafnium-based piezoelectric nano-particles UIO-66-NH2 etched by sulfuric acid, an anti-epileptic drug, a microglial cell membrane and transferrin receptor targeting peptide, wherein the anti-epileptic drug is loaded in hafnium-based piezoelectric nanoparticles etched by sulfuric acid to form a drug loading core; the microcolloid cell membrane coats the outer surface of the drug loading core; the transferrin receptor targeting peptide is connected to a microglial cell membrane. The ultrasonic response bionic piezoelectric nano-drug is high in brain entering efficiency, stable in drug release amount and clear in preparation method path, is suitable for targeted delivery of various anti-epileptic drugs and treatment and research of nervous system diseases such as epilepsy, can adopt an intravenous injection administration mode and non-invasive administration, can avoid injury caused by an operation, and has a good application prospect. The electrical stimulation is generated in vivo without implanting and taking out the electrode, so that secondary injury and infection are avoided.